Navigation Links
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
Date:6/16/2008

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced the appointment of Michael L. Kranda as president, chief executive officer and a member of the company's board of directors, effective June 16, 2008. Mr. Kranda succeeds John P. McLaughlin, who resigned as chief executive officer and member of the Anesiva board to pursue other business interests, while remaining a consultant to the company.

"Michael is the ideal person to lead Anesiva as it transitions from a drug development company to a commercially focused enterprise," said Rodney A. Ferguson, chairman of Anesiva's board. "He is a proven leader with extensive biotechnology experience and will be leading a great team here."

Mr. Kranda is a seasoned biopharmaceutical executive who brings two decades of commercial operating and corporate development experience to Anesiva. Most recently, he was Managing Director for biotechnology and life science investments at Vulcan, Inc. where he played an active role in the product, business development and financing activities of multiple portfolio companies. Before that, he was chief executive officer of Oxford GlycoSciences and led the transition of OGS from a biotech "tools" supply company to a leadership position in proteomics-based drug discovery and development. Prior to that, he served as president and chief operating officer and director at Immunex, where he built and managed sales, marketing, distribution, corporate development and manufacturing operations.

"With the upcoming commercial launch of Zingo(TM) and Adlea(TM) Phase 3 clinical milestones, Anesiva is poised to become a leader in the development and commercialization of novel pharmaceutical products for pain management," said Mr. Kranda. "I look forward to working with the talented employees of Anesiva to achieve these goals and build long-term value for stockholders."

"The members of the Anesiva board welcome Michael and thank John for his dedicated leadership over the last 8 years," said Mr. Ferguson. "We appreciate John's vision and dedication in leading Anesiva."

"I am proud of the significant accomplishments that the Anesiva team has made over the last several years," said Mr. McLaughlin. "With Michael in place to lead the company forward, I will work closely with him as a consultant to ensure a smooth transition."

About Anesiva's Diverse Pipeline of Pain Products

Anesiva, Inc. is a commercial-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first product, Zingo(TM), is scheduled for launch later this month in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The company filed an sNDA with the FDA to expand the label to include adults in March 2008.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the degree to which Zingo gains market acceptance and whether Zingo gains FDA approval for the adult indication, the timing and results of our Adlea clinical trials, and our regulatory approval strategy for Adlea. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007 and most recently quarterly report on Form 10-Q.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Fort Washington, PA (PRWEB) , ... ... ... The Omnia-Prova Education Collaborative (TOPEC), the leading medical education provider of ... Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). ...
(Date:2/22/2017)... 2017 Dublin - ... Biological Crop Protection (Bio-Pesticide) Market-By Type, By Application, By End User, ... their offering. ... Global Biological Crop Protection Market is forecasted to grow at a ... in biopesticide or biological crop protection market is driven by the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, ... , Perkins joins Pennside after more than a decade with leading market research ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... operational results for the three months ended December 31, 2016. ... -based life sciences and diagnostics company that develops and commercializes ... ... to build on the commercial milestones achieved in fiscal 2016," ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
Breaking Biology News(10 mins):